Dario Signs New Agreement with a Major Health Insurer in Arizona Representing Hundreds of Thousands of Lives Through Amwell Partnership

Rhea-AI Summary

DarioHealth (NASDAQ: DRIO) announced a new agreement with a major Arizona health insurer through its Amwell partnership, making its cardiometabolic digital health solution available to the insurer's ASO employer clients, representing access to hundreds of thousands of covered lives.

The deal supports Dario's channel-led, capital-efficient growth model, expanding recurring revenue opportunities and leveraging a network reaching over 116 million covered lives, with an employer ROI of up to 5x reported in a Sanofi-funded study.

Positive

• Access to hundreds of thousands of ASO covered lives via major Arizona insurer
• Reinforces channel-led growth strategy through Amwell partnership
• Expands recurring revenue opportunities within large employer populations
• Sanofi-funded study reports up to 5x ROI for employers
• More than 100 scientific studies validating Dario's cardiometabolic solution
• Channel network provides access to over 116 million covered lives
• Capital-efficient model lowering customer acquisition costs and accelerating sales cycles

Negative

• None.

News Market Reaction – DRIO

-1.51%

3 alerts

-1.51% Session close to close

-4.1% Trough Tracked

$53.23M Market Cap

1.5x Rel. Volume

In the Jul 6 session, DRIO declined 1.51%, reflecting a mild negative market reaction. Argus tracked a trough of -4.1% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The new Arizona ASO partnership extends Dario’s channel-led model, adding payer-scale reach on top o...

Analysis

The new Arizona ASO partnership extends Dario’s channel-led model, adding payer-scale reach on top of access to over 116 million covered lives and up to 5x ROI data, but an unused $100,000,000 shelf and ATM program keep financing risk in focus.

Key Figures

Employer ROI: up to 5x ROI Scientific studies: more than 100 studies Covered lives via channels: over 116 million covered lives

3 metrics

Employer ROI up to 5x ROI Study funded by Sanofi on Dario’s solution

Scientific studies more than 100 studies Peer-reviewed publications and conference abstracts validating solution

Covered lives via channels over 116 million covered lives Access through expanding channel partnership network

Previous Partnership Reports

3 past events · Latest: Jun 29 (Positive)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 29	partnership announcement	Positive	-3.3%	Collaborative services agreement with Beluga Health for integrated chronic care.
Oct 06	partnership announcement	Positive	-3.3%	Collaboration with OneStep to add fall risk assessment to platform.
Oct 01	partnership announcement	Positive	-10.7%	Multi-million-dollar Medicare Advantage behavioral health contract starting January 2025.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent partnership announcements have typically been followed by negative next-day moves despite fundamentally positive strategic content.

Key Terms

administrative services only, aso, return on investment, a1c, +1 more

5 terms

administrative services only financial

"available to the insurer's Administrative Services Only ("ASO") book of business"

Administrative services only (ASO) is a contract in which a company hires an insurance carrier or third-party administrator to handle the day-to-day paperwork and claims processing for an employee benefits plan while the company itself pays the actual claims costs. Think of it like hiring a bookkeeping firm to run payroll while you still fund the wages: the administrator manages operations and compliance, but the employer keeps the financial risk and cash-flow responsibility. For investors, ASO arrangements affect an employer’s balance sheet volatility, liquidity needs, and exposure to unexpected benefit costs.

aso financial

"available to the insurer's Administrative Services Only ("ASO") book of business"

An antisense oligonucleotide (ASO) is a short, lab-made strand of genetic material designed to bind a specific RNA message in cells and alter how a gene’s instructions are carried out. Investors care because ASO drugs aim to treat diseases by directly fixing or blocking faulty genetic signals; successful ASOs can create highly targeted, patent-protected treatments with big upside, while failures tend to be binary, making development risk and potential reward both high—like a custom key that either opens a valuable lock or doesn’t.

return on investment financial

"Dario uniquely delivers up to 5x return on investment ("ROI") to employers"

Return on investment measures the gain or loss you get from putting money into something, expressed as a percentage of the original cost. It matters to investors because it shows how efficiently capital is being used—like comparing how much fruit different trees produce per seed planted—helping decide which opportunities deliver more reward for each dollar and whether results beat expectations or benchmarks.

a1c medical

"improvements in key metrics, including systolic blood pressure, A1C and hyperglycemic events"

A1C is a blood test that reports average blood sugar over about three months by measuring how much glucose sticks to hemoglobin, a protein in red blood cells. For investors, A1C acts like a long-term scorecard for diabetes treatments, devices and diagnostics: meaningful changes in A1C in clinical studies can affect regulatory approval, insurance coverage and commercial prospects, and thus influence a company's market value.

hyperglycemic medical

"including systolic blood pressure, A1C and hyperglycemic events"

High blood sugar; a hyperglycemic state means the amount of glucose in the blood is above normal levels. Like an engine running with too much fuel, sustained high blood sugar can disrupt how the body’s organs and systems work and is a key marker in diabetes and metabolic conditions. For investors, hyperglycemia matters because it can drive demand for treatments, affect clinical trial outcomes, and influence regulatory and safety assessments for medical products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Agreement representative of Dario's channel-led growth strategy to bring cardiometabolic digital health solution at scale to self-insured employers seeking measurable reductions in cardiometabolic risk and total cost of care via payer relationships

NEW YORK, July 6, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced a new agreement with a major health insurer with a stronghold in Arizona, entered into through its strategic channel partnership with Amwell.  This opportunity makes Dario's cardiometabolic solution available to the insurer's Administrative Services Only ("ASO") book of business, representing access to hundreds of thousands of covered lives. 

"This agreement demonstrates how our channel strategy is driving scalable, efficient access to large employer populations," said Erez Raphael, Dario's Chief Executive Officer. "By leveraging channel partner infrastructure and relationships, we can rapidly reach a high-value ASO population like this and embed Dario within the health plan ecosystem. This approach enables us to expand recurring revenue opportunities while delivering measurable clinical and economic outcomes for employers and reinforces a repeatable model for growth across our expanding channel partnerships."

Dario's solution will be positioned as a differentiated offering within the insurer's ASO portfolio for employer clients seeking to address diabetes, hypertension and weight management through a unified, behaviorally-driven approach. Employers can adopt the solution based on their specific population needs and benefits strategy, with tailored deployments at scale. 

Dario uniquely delivers up to 5x return on investment ("ROI") to employers as demonstrated in a study funded by Sanofi and provides a clinically-grounded solution validated by more than 100 scientific studies, including peer reviewed journal publications and conference abstracts – which represents one of the largest bodies of published scientific evidence among all digital health companies. The savings seen by Dario clients are produced through fewer hospitalizations and improvements in key metrics, including systolic blood pressure, A1C and hyperglycemic events.

Leveraging Amwell's market reach, Dario advances its capital-efficient growth model that lowers customer acquisition costs, accelerates sales cycles and supports scalable expansion across employer populations. Dario has access to over 116 million covered lives through its expanding channel partnership network.

About DarioHealth Corp. (NASDAQ: DRIO)

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com. 

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the Company's expectations regarding the benefits of the agreement and collaboration with Amwell; the Company's expectations regarding employer adoption of its solutions; the Company's expectations regarding recurring revenue opportunities and scalable growth; the Company's expectations regarding the clinical and economic benefits of its solutions; and the Company's expectations regarding the expansion of its channel partnerships and access to covered lives. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310

Rob Halpern
SVP Marketing
irteam@dariohealth.com

Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/dario-signs-new-agreement-with-a-major-health-insurer-in-arizona-representing-hundreds-of-thousands-of-lives-through-amwell-partnership-302818159.html

SOURCE DarioHealth Corp.

FAQ

What did DarioHealth (NASDAQ: DRIO) announce on July 6, 2026 regarding an Arizona health insurer?

DarioHealth announced a new agreement with a major Arizona health insurer through its Amwell partnership, expanding access to its cardiometabolic solution. According to Dario, this agreement reaches the insurer's ASO employers, representing hundreds of thousands of covered lives seeking cardiometabolic risk and cost reductions.

How many covered lives could DarioHealth (DRIO) reach through the new Arizona insurer agreement?

The Arizona agreement gives DarioHealth access to hundreds of thousands of covered lives within the insurer's ASO business. According to Dario, this adds to a broader channel network that already provides access to over 116 million covered lives across multiple employer and payer relationships.

How does the Amwell partnership support DarioHealth's (DRIO) growth strategy?

The Amwell partnership acts as a strategic channel, enabling DarioHealth to reach large employer populations efficiently. According to Dario, leveraging Amwell's infrastructure lowers customer acquisition costs, accelerates sales cycles, and supports scalable expansion of its cardiometabolic solution across employer and health plan ecosystems.

What conditions does DarioHealth's (DRIO) cardiometabolic solution target for ASO employers?

DarioHealth's cardiometabolic solution targets diabetes, hypertension, and weight management for ASO employer populations. According to Dario, it uses a unified, behaviorally driven approach that employers can tailor to specific population needs and benefit strategies, aiming for measurable clinical and economic outcomes at scale.

What return on investment does DarioHealth (DRIO) report for employers using its solution?

DarioHealth reports that employers can see up to a 5x ROI from its cardiometabolic solution. According to Dario, a Sanofi-funded study attributes savings to fewer hospitalizations and improvements in systolic blood pressure, A1C levels, and hyperglycemic events across participating populations.

How much scientific validation supports DarioHealth's (DRIO) digital health platform?

DarioHealth reports its solution is validated by more than 100 scientific studies, including peer-reviewed publications. According to Dario, this represents one of the largest evidence bases among digital health companies, supporting its clinically grounded approach to cardiometabolic risk reduction and employer-focused health outcomes.

How does the new insurer agreement affect DarioHealth's (DRIO) recurring revenue opportunities?

The new agreement is described as expanding recurring revenue opportunities by embedding Dario's solution in a major health plan ecosystem. According to Dario, the channel-led model allows scalable, repeatable employer deployments that can drive ongoing revenue tied to cardiometabolic digital health services.